Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Wealthfront Advisers LLC

Wealthfront Advisers LLC increased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 24.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,302 shares of the biopharmaceutical company’s stock after acquiring an additional 2,006 shares during the quarter. Wealthfront Advisers LLC’s holdings in Alnylam Pharmaceuticals were worth $2,507,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Atria Investments Inc raised its holdings in Alnylam Pharmaceuticals by 78.9% in the 3rd quarter. Atria Investments Inc now owns 3,145 shares of the biopharmaceutical company’s stock valued at $865,000 after buying an additional 1,387 shares during the period. GSA Capital Partners LLP raised its holdings in Alnylam Pharmaceuticals by 55.3% in the 3rd quarter. GSA Capital Partners LLP now owns 2,860 shares of the biopharmaceutical company’s stock valued at $787,000 after buying an additional 1,018 shares during the period. Sumitomo Mitsui Trust Group Inc. raised its holdings in Alnylam Pharmaceuticals by 0.5% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 278,241 shares of the biopharmaceutical company’s stock valued at $76,525,000 after buying an additional 1,294 shares during the period. Victory Capital Management Inc. raised its holdings in Alnylam Pharmaceuticals by 10.9% in the 3rd quarter. Victory Capital Management Inc. now owns 42,909 shares of the biopharmaceutical company’s stock valued at $11,801,000 after buying an additional 4,229 shares during the period. Finally, Oppenheimer & Co. Inc. increased its stake in Alnylam Pharmaceuticals by 11.1% during the third quarter. Oppenheimer & Co. Inc. now owns 1,906 shares of the biopharmaceutical company’s stock worth $524,000 after purchasing an additional 190 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insiders Place Their Bets

In other news, Director Phillip A. Sharp sold 11,250 shares of the firm’s stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the firm’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the transaction, the executive vice president now owns 14,321 shares of the company’s stock, valued at approximately $3,654,862.41. This represents a 4.42 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 71,234 shares of company stock worth $19,958,097. 1.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have issued reports on ALNY shares. Royal Bank of Canada reiterated an “outperform” rating and set a $310.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Chardan Capital reiterated a “buy” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Canaccord Genuity Group boosted their price target on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the stock a “buy” rating in a research note on Tuesday, February 18th. StockNews.com upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday. Finally, Morgan Stanley boosted their price target on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twenty have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $304.26.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $241.76 on Friday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The business has a 50 day simple moving average of $255.02 and a 200-day simple moving average of $260.44. The stock has a market capitalization of $31.30 billion, a PE ratio of -111.41 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.